This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/national-drug-code-directory/
n28http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/chebi/
n20http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n22http://www.drugs.com/mtm/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/bindingdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/kegg-compound/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/pubchem-compound/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/kegg-drug/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/pubchem-substance/
n6http://linked.opendata.cz/resource/drugbank/property/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00933/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00933
rdf:type
n3:Drug
n3:description
A phenothiazine antipsychotic with effects similar to chlorpromazine. [PubChem]
n3:group
approved
n3:halfLife
24 to 48 hours
n3:indication
Used in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.
n3:manufacturer
n17:271B63A7-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00933 n20:DB00933
dcterms:title
Mesoridazine
adms:identifier
n5:DB00933 n7:6780 n8:3936 n9:0597-0020-01 n12:PA450386 n13:C07143 n14:D02671 n16:Mesoridazine n23:50131440 n26:4078 n27:46506724
n3:mechanismOfAction
Based upon animal studies, mesoridazine, as with other phenothiazines, acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex. In addition, the phenothiazines exhibit at least part of their activities through depression of hypothalamic centers. Neurochemically, the phenothiazines are thought to exert their effects by a central adrenergic blocking action.
n3:packager
n17:271B63A5-363D-11E5-9242-09173F13E4C5 n17:271B63A6-363D-11E5-9242-09173F13E4C5
n3:synonym
2-Methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10H-phenothiazine thioridazine-2-sulfoxide Thioridazine Thiomethyl Sulfoxide TPS-23 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine Mesoridazinum Mesoridazine Mesoridazina
n3:toxicity
Oral LD<sub>50</sub> is 560 &plusmn; 62.5 mg/kg and 644 &plusmn; 48 mg/kg in mouse and rat, respectively. Symptoms of overdose may include emesis, muscle tremors, decreased food intake and death associated with aspiration of oral-gastric contents into the respiratory system.
n3:foodInteraction
Take with food to reduce irritation.
n3:proteinBinding
4%
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Mesoridazine.htm
n10:hasConcept
n11:M0013483
foaf:page
n22:mesoridazine.html n28:mesoridazine.htm
n3:IUPAC-Name
n6:271B63AC-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B63B2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B63B1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B63AE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B63AF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B63B0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B63AA-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B63C2-363D-11E5-9242-09173F13E4C5 n6:271B63AB-363D-11E5-9242-09173F13E4C5 n6:271B63A8-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B63A9-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:N05AC03
n3:H-Bond-Acceptor-Count
n6:271B63B8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B63B9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B63B3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B63B4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B63B6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B63B5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B63B7-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
5588-33-0
n3:category
n3:Bioavailability
n6:271B63BE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B63C0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B63C1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B63BD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B63BC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B63BF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B63AD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B63BA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B63BB-363D-11E5-9242-09173F13E4C5